Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Irl Brian Greenwell"'
Autor:
Narendranath Epperla, Rina Li Welkie, Pallawi Torka, Geoffrey Shouse, Reem Karmali, Lauren Shea, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reaves, Montreh Tavakkoli, Kathryn Lindsey, Irl Brian Greenwell, Emily Hansinger, Colin Thomas, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Alex F. Herrera, Natalie S. Grover, Adam J. Olszewski
Publikováno v:
Journal of Hematology & Oncology, Vol 16, Iss 1, Pp 1-6 (2023)
Abstract Progression of disease within 24 months (POD24) from diagnosis in marginal zone lymphoma (MZL) was shown to portend poor outcomes in prior studies. However, many patients with MZL do not require immediate therapy, and the time from diagnosis
Externí odkaz:
https://doaj.org/article/4835afa60d3d4971aa7119bfb3356cb7
Autor:
Narendranath Epperla, Qiuhong Zhao, Sayan Mullick Chowdhury, Lauren Shea, Tamara K. Moyo, Nishitha Reddy, Julia Sheets, David M. Weiner, Praveen Ramakrishnan Geethakumari, Malathi Kandarpa, Ximena Jordan Bruno, Colin Thomas, Michael C. Churnetski, Andrew Hsu, Luke Zurbriggen, Cherie Tan, Kathryn Lindsey, Joseph Maakaron, Paolo F. Caimi, Pallawi Torka, Celeste Bello, Sabarish Ayyappan, Reem Karmali, Seo-Hyun Kim, Anna Kress, Shalin Kothari, Yazeed Sawalha, Beth Christian, Kevin A. David, Irl Brian Greenwell, Murali Janakiram, Vaishalee P. Kenkre, Adam J. Olszewski, Jonathon B. Cohen, Neil Palmisiano, Elvira Umyarova, Ryan A. Wilcox, Farrukh T. Awan, Juan Pablo Alderuccio, Stefan K. Barta, Natalie S. Grover, Nilanjan Ghosh, Nancy L. Bartlett, Alex F. Herrera, Geoffrey Shouse
Publikováno v:
Journal of Hematology & Oncology, Vol 15, Iss 1, Pp 1-6 (2022)
Abstract Ibrutinib is effective in the treatment of relapsed/refractory (R/R) marginal zone lymphoma (MZL) with an overall response rate (ORR) of 48%. However, factors associated with response (or lack thereof) to ibrutinib in R/R MZL in clinical pra
Externí odkaz:
https://doaj.org/article/742e9377f2884da1b8eeb0b6ff560e57
Autor:
Pamela B. Allen, Subir Goyal, Swaminathan P. Iyer, Sai Talluru, Auris Huen, Irl Brian Greenwell, Jane Scribner, Shel Speegle, Tim Niyogusaba, Sunil Rangarajan, Amitkumar Mehta, Colin B. O'Leary, Anne W. Beaven, Jeffrey M. Switchenko, Amy Ayers, Safiyyah Bhatti, Shalini Krishnasamy, Pierluigi Porcu, Tarsheen Sethi, Francine M. Foss, Mary Jo Lechowicz, Sima Rozati
Publikováno v:
Blood. 140:9431-9433
Autor:
Narendranath Epperla, Rui Li, Pallawi Torka, Lauren Shea, Reem Karmali, Andrea Anampa-Guzman, Timothy Seijung Oh, Kathryn Lindsey, Irl Brian Greenwell, Sayan Mullick Chowdhury, Kaitlin Annunzio, Beth Christian, Geoffrey Shouse, Alex F. Herrera, Nancy L. Bartlett, Natalie S. Grover, Adam J. Olszewski
Publikováno v:
Blood. 140:1926-1928
Autor:
Narendranath Epperla, Qiuhong Zhao, Lauren Shea, Reem Karmali, Pallawi Torka, Timothy Seijung Oh, Andrea Anampa-Guzman, Ximena Jordan Bruno, Elvira Umyarova, Kathryn Lindsey, Irl Brian Greenwell, Sayan Mullick Chowdhury, Yazeed Sawalha, Beth Christian, Natalie S. Grover, Nancy L. Bartlett, Adam J. Olszewski
Publikováno v:
Blood. 140:420-422
Autor:
Yazeed Sawalha, Subir Goyal, Jeffrey M. Switchenko, Jason T. Romancik, Manali Kamdar, Irl Brian Greenwell, Brian T. Hess, Krista M. Isaac, Craig A. Portell, Alex V. Mejia Garcia, Scott R Goldsmith, Natalie S. Grover, Peter A. Riedell, Reem Karmali, Madelyn Burkart, Michael Buege, Othman S. Akhtar, Pallawi Torka, Anita Kumar, Brian T. Hill, Brad S. Kahl, Jonathon B. Cohen
Publikováno v:
Blood Advances.
To report the activity of venetoclax in patients with relapsed mantle cell lymphoma (MCL), we identified 81 patients treated with venetoclax monotherapy (n=50, 62%) or in combination with a BTK inhibitor (n=16, 20%), an anti-CD20 monoclonal antibody
Autor:
Lindsey Hendrickson, Iya Znoyko, James Kalmuk, Daynna J. Wolff, Irl Brian Greenwell, Zane Chiad, Cynthia A. Schandl, Sandra Mazzoni, Nina D. Wagner-Johnston, Brian T. Hess
Publikováno v:
Cancer Genetics. :18-22
Richter transformation (RT) refers to the development of an aggressive lymphoma in patients with pre-existing chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). It carries a poor prognosis secondary to poor response to therapy or rapi
Autor:
Irl Brian Greenwell, Jeffrey M. Switchenko, Alexander F.M. Craig, Ash A. Alizadeh, Pamela B. Allen, Alicia Escobar, Kelly Valla, Aseala Abousaud, Priya Parikh, Danielle Roberts, Jessica J. Neely, Alexandra Palmer, Kristie A. Blum, Jonathon B. Cohen, Marcela Algave
Publikováno v:
Blood. 140:9373-9374
Autor:
Madelyn Burkart, Krista Isaac, Jason T. Romancik, Jeffrey M. Switchenko, Brad S. Kahl, Scott R. Goldsmith, Natalie S Grover, Reem Karmali, Othman S. Akhtar, Yazeed Sawalha, Craig A. Portell, Manali Kamdar, Peter A. Riedell, Brian T. Hill, Brian T. Hess, Pallawi Torka, Subir Goyal, Irl Brian Greenwell, Jonathon B. Cohen, Anita Kumar, Alex V. Mejia Garcia, Michael J Buege
Publikováno v:
Blood. 136:4-6
Background Limited data are available on the clinical activity of venetoclax (ven) in mantle cell lymphoma (MCL). In 2 small retrospective studies of patients (pts) with MCL previously treated with BTK inhibitors (BTKi), ven resulted in overall respo
Autor:
Mary McGann, Kelly Gaffney, James A Davis, Natasha Weathers, Irl Brian Greenwell, Brian Hess, Hamza Hashmi
Publikováno v:
Transplantation and Cellular Therapy. 28:S191-S192